The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)
Open accessAbstract
Despite continuing efforts during the last decades, there is no ‘ideal prosthetic valve substitute’. Every valve prosthesis invokes new pathophysiological processes, including the risks of thromboembolism, prosthetic endocarditis, and structural valve deterioration (SVD) or non-structural valve deterioration with consequent need for reintervention (Figure 1). Bioprostheses are now increasingly used in preference to mechanical valves in the aortic position but valve dysfunction may occur over time. The literature concerning surgical prostheses has taught us that bioprosthetic valve dysfunction is a complex phenomenon whose understanding requires more than the reporting of reintervention. Further research must encompass biological, pathological and haemodynamic mechanisms, use of contemporary non-invasive imaging, evaluation of the true incidence while avoiding methodological pitfalls, and identification of clinical, technical, and prosthesis-specific predictors. Causes of bioprosthetic valve dysfunction. Since introduction in 2002 and broader clinical use in 2007, penetration of transcatheter aortic valve implantation (TAVI) has grown exponentially as a result of accruing evidence demonstrating safety and efficacy, and reduced invasiveness compared with surgery. TAVI is now the recommended therapy in elderly patients with aortic stenosis who are inoperable or at increased surgical risk1 and recent evidence has demonstrated at least its equivalence to surgery in intermediate and high-risk cohorts.2–4 However, our knowledge concerning the clinical outcomes of TAVI beyond 5 years is still limited. Although SVD is likely to be the main mechanism of bioprosthetic valve dysfunction in the longer term, definitions of SVD vary and follow-up studies are scarce. While it is possible to draw lessons from longer term experience with surgical bioprostheses, there are fundamental differences between TAVI and surgical aortic valve replacement (SAVR) (i.e. remaining valve calcification, mechanical stress, crimping of the valve tissue, valve leaflet geometry, balloon expansion or dilation, differences in haemodynamic profile, and patient-prosthesis mismatch), which may impact on the natural history of SVD (see Supplementary material online, Appendix). Critically, extended knowledge of the durability of TAVI is essential as we enter the time (>5 years after implantation) when SVD starts to occur in surgical bioprostheses. This knowledge assumes even greater importance as we consider expanding the indications for TAVI to lower risk and younger patients. As such, standardizing the definitions of valve- and patient-oriented durability outcomes is of paramount importance to enable objective evaluation of existing and novel TAVI prostheses, and their comparative efficacy vs. SAVR. In this context, the European Association of Percutaneous Cardiovascular Intervention (EAPCI) determined that improved characterization of long-term TAVI outcomes was timely. Two face-to-face meetings (September 2016, London; January 2017, Frankfurt) involving members of the EAPCI, the European Society of Cardiology (ESC), and the European Association for Cardio-Thoracic Surgery (EACTS) representing interventional cardiology, clinical cardiology, imaging and surgery, provided much of the discussion to inform the present document. Herein, we present the available evidence on TAVI SVD, addressed in terms of existing definitions, predictors, and detection. In parallel, we present a standardized definition of SVD and a new patient-oriented clinical end point named bioprosthetic valve failure (BVF) for use in future studies, which aims to capture the clinically relevant manifestations and consequences of SVD or other forms of bioprosthetic valve dysfunction. This effort precedes a registry initiated within the ESC European Observational Registries Programme (EORP) which will evaluate the incidence, presentation, mode, and timing of bioprosthetic valve dysfunction in a contemporary real-world setting. The ultimate goals of this multidisciplinary collaboration are to improve the characterization of SVD and BVF in line with similar ongoing efforts by the Valve Academic Research Consortium (VARC) 3 and optimize the future utilization of TAVI. Survival without valve reintervention or explant for SVD is an outcome still used by some published series to assess the durability of surgical bioprostheses.5 However, surgical guidelines for event reporting after cardiac valve interventions have not supported this approach since 2008, and stipulate that SVD should also be defined by clinically detectable measures other than the need for reoperation for a failing bioprosthesis (i.e. using echocardiographic criteria).6 In 2009, Zoghbi et al . 7 published a series of recommendations for the evaluation of prosthetic valves using echocardiography and Doppler ultrasound. Possible stenosis was defined as peak prosthetic aortic jet velocity 3–4 m/s, mean gradient 20–35 mmHg, and e
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients
Leon, M. B., Smith, C. R., Mack, M. J., Makkar, R. R., Svensson, L. G., Kodali, S. K., Thourani, V. H., Tuzcu, E. M., Miller, D. C., Herrmann, H. C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1514616 · Cited by 5,053
Habib, G., Lancellotti, P., Antunes, M. J., Bongiorni, M. G., Casalta, J.-P., Del Zotti, F., Dulgheru, R., El Khoury, G., Erba, P. A., Iung, B., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv319 · Cited by 4,997
Self-citationGuidelines on the management of valvular heart disease (version 2012)
Authors/Task Force Members, Vahanian, A., Alfieri, O., Andreotti, F., Antunes, M. J., Barón-Esquivias, G., Baumgartner, H., Borger, M. A., Carrel, T. P., De Bonis, M., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs109 · Cited by 3,559
Self-citationKappetein, A. P., Head, S. J., Généreux, P., Piazza, N., Mieghem, N. M. V., Blackstone, E., Brott, T., Cohen, D., Cutlip, D. E., van Es, G., et al. (2012) · doi:10.48350/15011 · Cited by 3,368
Self-citationSurgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients
Reardon, M. J., Van Mieghem, N. M., Popma, J. J., Kleiman, N. S., Søndergaard, L., Mumtaz, M., Adams, D. H., Deeb, G. M., Maini, B., Gada, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700456 · Cited by 3,009
Self-citationMack, M. J., Leon, M. B., Smith, C. R., Miller, D. C., Moses, J. W., Tuzcu, E. M., Webb, J. G., Douglas, P. S., Anderson, W. N., Blackstone, E. H., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60308-7 · Cited by 1,739
Recommendations for Evaluation of Prosthetic Valves With Echocardiography and Doppler Ultrasound
Zoghbi, W. A., Chambers, J. B., Dumesnil, J. G., Foster, E., Gottdiener, J. S., Grayburn, P. A., Khandheria, B. K., Levine, R. A., Marx, G. R., Miller, F. A., et al. (2009) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2009.07.013 · Cited by 1,259
Kappetein, A. P., Head, S. J., Généreux, P., Piazza, N., van Mieghem, N. M., Blackstone, E. H., Brott, T. G., Cohen, D. J., Cutlip, D. E., van Es, G.-A., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs255 · Cited by 1,043
Self-citationTranscatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Valve Stenosis
Thyregod, H. G. H., Steinbrüchel, D. A., Ihlemann, N., Nissen, H., Kjeldsen, B. J., Petursson, P., Chang, Y., Franzen, O. W., Engstrøm, T., Clemmensen, P., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.014 · Cited by 933
Guidelines for reporting mortality and morbidity after cardiac valve interventions
Akins, C. W., Miller, D. C., Turina, M. I., Kouchoukos, N. T., Blackstone, E. H., Grunkemeier, G. L., Takkenberg, J. J. M., David, T. E., Butchart, E. G., Adams, D. H., et al. (2008) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2007.12.002 · Cited by 665
Cited by
2017 ESC/EACTS Guidelines for the management of valvular heart disease
Baumgartner, H., Falk, V., Bax, J. J., De Bonis, M., Hamm, C., Holm, P. J., Iung, B., Lancellotti, P., Lansac, E., Rodriguez Muñoz, D., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx391 · Cited by 6,243
Self-citation2021 ESC/EACTS Guidelines for the management of valvular heart disease
Vahanian, A., Beyersdorf, F., Praz, F., Milojevic, M., Baldus, S., Bauersachs, J., Capodanno, D., Conradi, L., De Bonis, M., De Paulis, R., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab395 · Cited by 5,685
Self-citationTranscatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients
Mack, M. J., Leon, M. B., Thourani, V. H., Makkar, R., Kodali, S. K., Russo, M., Kapadia, S. R., Malaisrie, S. C., Cohen, D. J., Pibarot, P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814052 · Cited by 4,847
Généreux, P., Piazza, N., Alu, M. C., Nazif, T., Hahn, R. T., Pibarot, P., Bax, J. J., Leipsic, J. A., Blanke, P., Blackstone, E. H., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.038 · Cited by 1,313
Self-citation2025 ESC/EACTS Guidelines for the management of valvular heart disease
Praz, F., Borger, M. A., Lanz, J., Marin-Cuartas, M., Abreu, A., Adamo, M., Ajmone Marsan, N., Barili, F., Bonaros, N., Cosyns, B., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf194 · Cited by 1,072
Self-citation
Metadata
- Authors
- Capodanno, D., Petronio, A. S., Prendergast, B., Eltchaninoff, H., Vahanian, A., Modine, T., Lancellotti, P., Sondergaard, L., Ludman, P. F., Tamburino, C., Piazza, N., Hancock, J., Mehilli, J., Byrne, R. A., Baumbach, A., Kappetein, A. P., Windecker, S., Bax, J., & Haude, M.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-07-21
- Volume
- 38
- Issue
- 45
- Pages
- 3382-3390
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2737109842
- Cited by
- 535
- References
- 27
- FWCI
- 40.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). https://app.cochat.ai/papers/10.1093/eurheartj/ehx303
- The paper
- Capodanno, D., Petronio, A. S., Prendergast, B., Eltchaninoff, H., Vahanian, A., Modine, T., Lancellotti, P., Sondergaard, L., Ludman, P. F., Tamburino, C., Piazza, N., Hancock, J., Mehilli, J., Byrne, R. A., Baumbach, A., Kappetein, A. P., Windecker, S., Bax, J., & Haude, M. (2017). Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. https://doi.org/10.1093/eurheartj/ehx303
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.